Fig. 5: MCL-1 deletion increases responses to BCL-XL in vivo.

A MSTO-211H cells (with Cas9/MCL-1 sgRNA) tumour volumes measured during and following treatment with A-1331852 (25 mg/kg, 14 days by oral gavage), feeding doxycycline-containing chow, or appropriate controls. B Tumour masses at Day 19 (i.e. 1 day after the final dose of A-1331852 or vehicle administration). Each point is the mass of an individual tumour (photographed) with the bar indicating the mean ± SEM (n = 3). Significance determined by Student’s t-test (unpaired). C Kaplan–Meier survival curves with log-rank analysis of mice treated with A-1331852, doxycycline and combinations of both, with relevant vehicle controls. Survival endpoint was when tumours reached 1000 mm³ as dictated by the ethics approval associated with this experiment. Significance determined by Log-rank (Mantel–Cox test). D Immunohistochemistry analysis of tumours for cleaved Caspase-3 and Ki67. Values represent the mean % postively stained cells for each antibody in five different fields of view. Data are mean ± SEM (n = 3), significance determined by Student’s t-test (unpaired). ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05.